CAS No.116-26-7|SAFRANAL
Safranal has been shown to be cytotoxic to k562 cells, human serum, and ischemia–reperfusion injury. Safranal also has demonstrated an inhibitory effect on MDA-MB-231 breast cancer cells. Safranal can be used as a pharmacological agent for the treatment of various diseases or conditions associated with reactive oxygen species (ROS). The antioxidative properties of safranal have been demonstrated by its ability to protect crocin from oxidation.
2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxaldehyde;
2,6,6-trimethylcyclohexa-1,3-dienecarbaldehyde;
2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde;
2,3-Dihydro-2,2,6-trimethylbenzaldehyde;
1,3-CYCLOHEXADIENE-1-CARBOXALDEHYDE,2,6,6-TRIMETHYL;
FEMA No. 3389;
2,6,6-Trimethylcyclohexa-1,3-dienyl methanal;
1,3-Cyclohexadiene-1-carboxaldehyde, 2,6,6-trimethyl-;
1,1,3-Trimethyl-2-formylcyclohexa-2,4-diene;
CAS No.116-26-7|SAFRANAL
|
116-26-7 |
|
|
C10H14O |
|
|
150.22 |
|
|
<25 °C |
|
|
70 degree 1 mm Hg(lit.) |
|
|
0.966 g/mL at 25 degree (lit.) |
|
|
n20/D 1.523(lit.) |
|
|
186 degree F |
P CAS No.116-26-7|SAFRANAL
Package:0.1g,1g,5g,25g,100g,500g,1kg
CAS No.116-26-7|SAFRANAL
D Cerdá-Bernad, E Valero-Cases… - Critical Reviews in …, 2022 - Taylor & Francis
… of safranal has been evaluated in some studies. The acute and sub-acute toxicity of safranal
was … The acute toxicity during 2 d with different doses of safranal administered orally and …
人気ラベル: cas no.116-26-7|safranal, China cas no.116-26-7|safranal manufacturers, factory
